Sana Biotechnology Stock Buy Hold or Sell Recommendation
| SANA Stock | USD 8.58 0.49 6.06% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Sana Biotechnology is 'Cautious Hold'. Macroaxis provides Sana Biotechnology buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding SANA positions. The advice algorithm takes into account all of Sana Biotechnology's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Sana Biotechnology's buy or sell advice are summarized below:
Real Value 9.21 | Target Price 10 | Hype Value 8.32 | Market Value 8.58 | Naive Value 7.18 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Sana Biotechnology given historical horizon and risk tolerance towards Sana Biotechnology. When Macroaxis issues a 'buy' or 'sell' recommendation for Sana Biotechnology, the advice is generated through an automated system that utilizes algorithms and statistical models.
Sana |
Execute Sana Biotechnology Buy or Sell Advice
The Sana recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Sana Biotechnology. Macroaxis does not own or have any residual interests in Sana Biotechnology or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Sana Biotechnology's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Good | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Sana Biotechnology Trading Alerts and Improvement Suggestions
| Sana Biotechnology is way too risky over 90 days horizon | |
| Sana Biotechnology appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (283.25 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Sana Biotechnology currently holds about 484.8 M in cash with (253.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.57. | |
| Sana Biotechnology has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of the company shares are owned by institutional investors | |
| Latest headline from bizjournals.com: Sana Biotechnology RD leader Douglas Williams steps down |
Sana Biotechnology Returns Distribution Density
The distribution of Sana Biotechnology's historical returns is an attempt to chart the uncertainty of Sana Biotechnology's future price movements. The chart of the probability distribution of Sana Biotechnology daily returns describes the distribution of returns around its average expected value. We use Sana Biotechnology price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Sana Biotechnology returns is essential to provide solid investment advice for Sana Biotechnology.
| Mean Return | 0.88 | Value At Risk | -7.1 | Potential Upside | 12.25 | Standard Deviation | 5.94 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Sana Biotechnology historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Sana Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sana Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sana Biotechnology backward and forwards among themselves. Sana Biotechnology's institutional investor refers to the entity that pools money to purchase Sana Biotechnology's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Millennium Management Llc | 2023-12-31 | 2.2 M | Baker Bros Advisors Lp | 2023-12-31 | 2 M | Goldman Sachs Group Inc | 2023-12-31 | 1.7 M | Suvretta Capital Management, Llc | 2023-12-31 | 1.6 M | Capital World Investors | 2023-12-31 | 1.5 M | Partner Fund Management Lp | 2023-09-30 | 1.2 M | Jpmorgan Chase & Co | 2023-12-31 | 1.2 M | Massachusetts Financial Services Company | 2023-12-31 | 1.1 M | Northern Trust Corp | 2023-12-31 | 887 K | Flagship Ventures Management, Inc. | 2023-09-30 | 25 M | Fmr Inc | 2023-12-31 | 15.8 M |
Sana Biotechnology Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (58.5M) | (228.7M) | (211.4M) | 231.4M | 172.0M | 180.6M | |
| Change In Cash | 50.4M | 45.1M | 134.9M | (74.6M) | (45.5M) | (43.2M) | |
| Depreciation | 1.8M | 5.9M | 11.1M | 15.6M | 30.9M | 32.4M | |
| Capital Expenditures | 26.2M | 23.9M | 29.9M | 20.9M | 20.0M | 22.3M | |
| Net Income | (130.8M) | (285.3M) | (355.9M) | (269.5M) | (283.3M) | (297.4M) | |
| End Period Cash Flow | 81.8M | 126.9M | 261.8M | 187.3M | 137.3M | 151.6M | |
| Change To Netincome | 32.9M | 135.2M | 51.1M | 25.7M | 29.5M | 53.9M |
Sana Biotechnology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Sana Biotechnology or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Sana Biotechnology's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Sana stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.51 | |
β | Beta against NYSE Composite | 4.32 | |
σ | Overall volatility | 6.11 | |
Ir | Information ratio | 0.13 |
Sana Biotechnology Volatility Alert
Sana Biotechnology exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Sana Biotechnology's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Sana Biotechnology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Sana Biotechnology Fundamentals Vs Peers
Comparing Sana Biotechnology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Sana Biotechnology's direct or indirect competition across all of the common fundamentals between Sana Biotechnology and the related equities. This way, we can detect undervalued stocks with similar characteristics as Sana Biotechnology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Sana Biotechnology's fundamental indicators could also be used in its relative valuation, which is a method of valuing Sana Biotechnology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Sana Biotechnology to competition |
| Fundamentals | Sana Biotechnology | Peer Average |
| Return On Equity | -0.72 | -0.31 |
| Return On Asset | -0.29 | -0.14 |
| Current Valuation | 1.68 B | 16.62 B |
| Shares Outstanding | 220.45 M | 571.82 M |
| Shares Owned By Insiders | 9.16 % | 10.09 % |
| Shares Owned By Institutions | 85.40 % | 39.21 % |
| Number Of Shares Shorted | 26.13 M | 4.71 M |
| Price To Book | 6.86 X | 9.51 X |
| EBITDA | (294.94 M) | 3.9 B |
| Net Income | (283.25 M) | 570.98 M |
| Cash And Equivalents | 484.8 M | 2.7 B |
| Cash Per Share | 2.57 X | 5.01 X |
| Total Debt | 104.1 M | 5.32 B |
| Debt To Equity | 0.18 % | 48.70 % |
| Current Ratio | 5.09 X | 2.16 X |
| Book Value Per Share | 1.45 X | 1.93 K |
| Cash Flow From Operations | (253.58 M) | 971.22 M |
| Short Ratio | 12.65 X | 4.00 X |
| Earnings Per Share | (1.46) X | 3.12 X |
| Target Price | 11.17 | |
| Number Of Employees | 328 | 18.84 K |
| Beta | 1.61 | -0.15 |
| Market Capitalization | 1.78 B | 19.03 B |
| Total Asset | 565.3 M | 29.47 B |
| Retained Earnings | (1.34 B) | 9.33 B |
| Working Capital | 149.03 M | 1.48 B |
| Net Asset | 565.3 M |
Note: Acquisition by Bishop Hans Edgar of 65000 shares of Sana Biotechnology subject to Rule 16b-3 [view details]
Sana Biotechnology Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Sana . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Sana Biotechnology Buy or Sell Advice
When is the right time to buy or sell Sana Biotechnology? Buying financial instruments such as Sana Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 56.4M | 96.3M | 47.2M | 44.9M | Total Assets | 1.1B | 822.7M | 565.3M | 677.9M |
Use Investing Ideas to Build Portfolios
In addition to having Sana Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run FinTech Thematic Idea Now
FinTech
High long term potential financial entities that are ranging from payment processing, investment management to commercial and investment banking. The FinTech theme has 81 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize FinTech Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Sana Biotechnology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Sana Stock analysis
When running Sana Biotechnology's price analysis, check to measure Sana Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sana Biotechnology is operating at the current time. Most of Sana Biotechnology's value examination focuses on studying past and present price action to predict the probability of Sana Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sana Biotechnology's price. Additionally, you may evaluate how the addition of Sana Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Sana Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sana Biotechnology. If investors know Sana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sana Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Return On Assets (0.29) | Return On Equity (0.72) |
The market value of Sana Biotechnology is measured differently than its book value, which is the value of Sana that is recorded on the company's balance sheet. Investors also form their own opinion of Sana Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Sana Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sana Biotechnology's market value can be influenced by many factors that don't directly affect Sana Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sana Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sana Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sana Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.